ARWR dramatically improved its net loss position while revenue declined by nearly half, suggesting a major operational restructuring or significant one-time charges in the prior year.
The substantial improvement in net income performance despite lower revenue indicates either the company eliminated major one-time expenses from the prior year or achieved significant operational efficiencies. The sharp reduction in capital expenditures from $141.5M to $22.7M suggests a strategic shift in investment priorities or completion of a major build-out phase.
ARWR's financial profile shows a dramatic turnaround with net losses improving substantially from -$599.5M to just -$1.6M, despite revenue declining nearly 49% to $16.1M. The company strengthened its balance sheet position with current assets growing 37% to $950.6M and cash increasing 28% to $184.4M, while current liabilities nearly doubled to $195.5M. The sharp 84% reduction in capital expenditures alongside higher R&D spending suggests the company is focusing resources on drug development rather than infrastructure investments.
Net income grew 99.7% — bottom-line growth signals improving overall business health.
Current liabilities surged 89.5% — significant near-term obligations; verify ability to meet short-term debt.
Capex reduced 84% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Revenue declined 48.6% — significant demand weakness or market share loss warrants investigation.
Current assets grew 36.7% — improving short-term liquidity or inventory/receivables build.
Cash grew 28.5% — improving liquidity position supports investment and shareholder returns.
Asset base grew 21.5% — expansion through organic growth, acquisitions, or capital deployment.
R&D investment increased 20% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →